Volume 3.49 | Dec 21

Prostate Cell News 3.49 December 21, 2012
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY
Combinatorial Antigen Recognition with Balanced Signaling Promotes Selective Tumor Eradication by Engineered T Cells
Investigators present a strategy to render T cells specific for a tumor in the absence of a truly tumor-restricted antigen. T cells were transduced with both a chimeric antigen receptor (CAR) that provides suboptimal activation upon binding of one antigen and a chimeric costimulatory receptor that recognizes a second antigen. Using the prostate tumor antigens PSMA and PSCA, they showed that co-transduced T cells destroy tumors that express both antigens but do not affect tumors expressing either antigen alone. [Nat Biotechnol] Abstract | Press Release

View Lectures, Tools, Protocols and Other Resources on the Human Immunology Portal (www.humanimmunologyportal.com)
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

FGF-2 Disrupts Mitotic Stability in Prostate Cancer through the Intracellular Trafficking Protein CEP57
Scientists showed that FGF-2 rapidly uncouples centrosome duplication from the cell division cycle in prostate cancer cells through CEP57, an intracellular FGF-2 binding and trafficking factor. [Cancer Res] Abstract

Androgen Receptor Degradation by the E3 Ligase CHIP Modulates Mitotic Arrest in Prostate Cancer Cells
The authors report that low dose 2-methoxyestradiol, an endogenous estrogen metabolite, induces mitotic arrest in prostate cancer cells involving activation of the E3 ligase CHIP (C-terminus of Hsp70-interacting protein) and degradation of the androgen receptor. [Oncogene] Abstract

Daxx Regulates Mitotic Progression and Prostate Cancer Predisposition
Deregulation of APC/C is frequently observed in cancer cells and is suggested to contribute to chromosome instability and cancer predisposition. Here, researchers identified Daxx as a novel APC/C inhibitor frequently overexpressed in prostate cancer. [Carcinogenesis] Abstract

Snake (Walterinnesia aegyptia) Venom-Loaded Silica Nanoparticles Induce Apoptosis and Growth Arrest in Human Prostate Cancer Cells
Scientists recently demonstrated that venom extracted from Walterinnesia aegyptia (WEV) either alone or in combination with silica nanoparticles (WEV+NP) mediated the growth arrest and apoptosis of breast cancer cells. In the present study, they evaluated the impact of WEV alone and WEV+NP on the migration, invasion, proliferation and apoptosis of prostate cancer cells. [Apoptosis] Abstract | Full Article

Prostaglandin E2 Induces Stromal Cell-Derived Factor-1 Expression in Prostate Stromal Cells by Activating Protein Kinase A and Transcription Factor Sp1
Recent reports indicate prostaglandin E2 (PGE2) can modulate tumor environment and promote angiogenesis through induction of stromal cell-derived factor 1 (SDF-1) production. The authors investigated the mechanism of PGE2-induced SDF-1 regulation in human prostate stromal cell and analyzed the effects in a stromal-epithelial interaction model. [Int J Biochem Cell Biol] Abstract

Androgens Promote Prostate Cancer Cell Growth through Induction of Autophagy
Scientists determined that androgens regulate overall cell metabolism and cell growth, in part, by increasing autophagy in prostate cancer cells. [Mol Endocrinol] Abstract

Ursolic Acid Sensitizes Prostate Cancer Cells to TRAIL-Mediated Apoptosis
Researchers investigated the sensitizing effects of ursolic acid, a pentacyclic triterpenoid found in many plants, on TRAIL-induced prostate cancer cell apoptosis. [Biochim Biophys Acta] Abstract

Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes
The authors investigated phenotypic changes associated with docetaxel-resistance in order to help determine the complexity of this problem and to assess the relevance of secreted exosomes in prostate cancer. [PLoS One] Full Article

Insulin Receptor Isoforms A and B as well as Insulin Receptor Substrates-1 and -2 Are Differentially Expressed in Prostate Cancer
In different cancers types, insulin receptor isoform composition or insulin receptor substrate (IRS) isoforms are different to healthy tissue. This may be a molecular link to increased cancer risk in diabetes and obesity. Since this is yet unclear for prostate cancer, the authors investigated IR isoform composition and IRS balance in prostate cancer compared to benign and tumor adjacent benign prostate tissue and brought this into relation to cell proliferation. [PLoS One] Full Article

CLINICAL RESEARCH

Long-Term Use of Angiotensin Receptor Blockers and the Risk of Cancer
The authors aimed to determine whether angiotensin receptor blockers are associated with an overall increased risk of the four most common cancers, namely, lung, colorectal, breast and prostate cancers, and to explore these effects separately for each cancer type. [PLoS One] Full Article

A Phase I Dose Escalation Trial of Vaccine Replicon Particles (VRP) Expressing Prostate-Specific Membrane Antigen (PSMA) in Subjects with Prostate Cancer
In this first in human trial, two cohorts of three patients with castration resistant metastatic prostate cancer metastatic to bone were treated with up to five doses of either 0.9 × 107 IU or 0.36 × 108 IU of PSMA-VRP at weeks 1, 4, 7, 10 and 18, followed by an expansion cohort of six patients treated with 0.36 × 108 IU of PSMA-VRP at weeks 1, 4, 7, 10 and 18. [Vaccine] Abstract

Detect 7 times more prostate epithelial progenitors with ProstaCult

REVIEWS
Adaptation or Selection-Mechanisms of Castration-Resistant Prostate Cancer
Current research is focused on not only understanding the cellular mechanisms of castration-resistant prostate cancer, but also defining critical pathways that can be targeted with combinatorial therapies in castration-resistant cancer cells. [Nat Rev Urol] Abstract
INDUSTRY NEWS

OncoGenex Announces Initiation of Randomized Phase II “PACIFIC” Study of OGX-427 in Combination with Zytiga® in Men with Metastatic Castrate-Resistant Prostate Cancer
OncoGenex Pharmaceuticals, Inc. announced the initiation of PACIFIC, an investigator-sponsored, randomized Phase II study evaluating OGX-427 in men with metastatic castrate-resistant prostate cancer who are experiencing a rising PSA while receiving Zytiga. [PR Newswire Association LLC] Press Release

Bayer Submits New Drug Application for Radium-223 Dichloride for the Treatment of Castration-Resistant Prostate Cancer with Bone Metastases
Bayer HealthCare announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for radium-223 dichloride, an investigational compound for the treatment of castration-resistant prostate cancer patients with bone metastases. [Bayer AG] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW StemCONN 2013: Realizing the Promise
April 4, 2013
New Haven, United States


Visit
our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Postdoctoral Position – Biomarkers in Prostate Cancer (Roswell Park Cancer Institute, Buffalo)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

PhD Student – Multi-Compartment Magnetic Resonance Imaging of Prostate Cancer (University of East Anglia)

Postdoctoral Position – Convergence of the ZMIZ1 and NOTCH1 Oathways at C-MYC in Acute T Lymphoblastic Leukemias (University of Michigan – Ann Arbor)


Recruit Top Talent : Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us